NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances Clinical Trials for PRO 140 for HIV Infection
Cytodyn (OTCQB: CYDY) is focused on enhancing the lives of people with infectious diseases through the development of new antibody treatments to battle human immunodeficiency virus (HIV) infection. An estimated 1.2 million people in the United States were living with HIV at the end of 2013, the most recent year for which this information is available. Cytodyn recently reported the first several patients have been treated in its phase 3 clinical trial with PRO 140, its proprietary drug that can significantly reduce viral burden in people infected with HIV. PRO 140 works by blocking the HIV co-receptor CCR5 on T-cells…







